Combined use of amlodipine and folic acid are significantly more efficacious than amlodipine alone in lowering plasma homocysteine and blood pressure among hypertensive patients with hyperhomocysteinemia and intolerance to ACEI: A multicenter, randomized, double-blind, parallel-controlled clinical trial.

Hyperhomocysteinemia with hypertension can synergistically increase the risk of stroke. The China stroke primary prevention trial showed that combining 0.8 mg folic acid (FA) with angiotensin-converting enzyme inhibitor (ACEI) can effectively lower plasma total homocysteine (tHcy) and blood pressure (BP); and reduce first stroke risk by additional 21% compared to ACEI alone. However, intolerance to ACEI is common in Asians and amlodipine can be alternative. This is a multicenter, randomized, double-blind, parallel-controlled clinical trial (RCT) which evaluated whether amlodipine combined with FA is more efficacious than amlodipine alone in lowering tHcy and BP among Chinese hypertensive with hyperhomocysteinemia and intolerance to ACEI. 351 Eligible patients were randomly assigned by 1:1:1 ratio to receive amlodipine-FA tablet daily (amlodipine 5 mg/FA 0.4 mg, A group); amlodipine 5 mg/FA 0.8 mg tablet daily (B group); amlodipine 5 mg daily (C group, control group). Follow-up was conducted at 2, 4, 6, and 8 weeks. The primary outcome was efficacy of lowering both tHcy and BP at the end of 8-week treatment. Compared with C group, A group had a significantly higher rate of lowering both tHcy and BP (23.3% vs. 6.0%; Odds Ratio [OR], 8.68; 95% CI, 3.04-24.78, P < .001); B group also had a higher rate of lowering both tHcy and BP (20.3% vs. 6.0%; OR: 5.90; 95% CI, 2.11-16.47, P < .001). This RCT showed amlodipine combined with FA compared with amlodipine alone, each had significantly higher efficacy of lowering both tHcy and BP. No difference was found in BP-lowering and occurrence of adverse events between the three groups.

Highly efficient removal of oxytetracycline using activated magnetic MIL-101(Fe)/γ-Fe2O3 heterojunction catalyst.

A novel magnetic nanocomposite MIL-101(Fe)/γ-Fe2O3 was synthesized by hydrothermal method. The physical structure and chemical property of the as-obtained magnetic nanocomposite was characterized. The ability of MIL-101(Fe)/γ-Fe2O3 to promote photo-assisted peroxydisulfate (PDS) activation was investigated by using oxytetracycline (OTC) as the target pollutant. The results showed that the composite with a FeCl3•6H2O: γ-Fe2O3 mass ratio of 10:1 exhibited the highest degradation efficiency (up to 91.2%). Influencing factors such as pH, catalyst dosage, PDS concentration and OTC concentration on the catalytic performance of MIL-101(Fe)/γ-Fe2O3 were also investigated to determine the optimum conditions. More importantly, the MIL-101(Fe)/γ-Fe2O3 can be magnetically recovered and reused for 4 cycles. Based on radical quenching and electron spin resonance (ESR), the possible degradation mechanism of OTC in photo-assisted PDS activation (PPA) system was proposed. This research provided novel insights for the design and preparation of a new type of magnetic Fe-MOFs for environmental remediation.